LIDEX
LOE ApproachingNDATOPICALOINTMENT
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical ointment formulation approved in 1971 for dermatological indications. The specific mechanism of action and therapeutic uses are not publicly detailed in available data. As a small-molecule topical product, it likely treats inflammatory or infectious skin conditions.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30%), suggesting declining team investment and potential restructuring ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect LIDEX's mature, declining lifecycle stage under Alvogen sponsorship. Career opportunities on this product are minimal; roles would focus on defensive brand management, pricing strategy, and market access optimization rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.